SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+3.98%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$741M
AUM Growth
+$741M
(+15%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
21.02%
Top 10 Holdings %
Top 10 Hldgs %
44.76%
Holding
95
New
21
Increased
23
Reduced
18
Closed
26
Top Buys
| 1 |
FibroGen
FGEN
|
$21.9M |
| 2 |
Smith & Nephew
SNN
|
$20.5M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$19.3M |
| 4 |
Lantheus
LNTH
|
$15.5M |
| 5 |
CVS Health
CVS
|
$14.2M |
Top Sells
| 1 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$12.7M |
| 2 |
NeoGenomics
NEO
|
$9.19M |
| 3 |
CareDx
CDNA
|
$8.03M |
| 4 |
Cytosorbents Corp
CTSO
|
$6.5M |
| 5 |
C4 Therapeutics
CCCC
|
$6.1M |
Sector Composition
| 1 | Healthcare | 95.46% |
| 2 | Financials | 0.86% |
| 3 | Consumer Staples | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Lantheus
LNTH
$3.73B
| $51M | 5.1% | 1,764,627 +534,800 | +43% | +$15.5M |
|
2
ESSA Pharma
EPIX
$11.4M
| $50.1M | 5.01% | 3,525,457 +657,434 | +23% | +$9.34M |
|
3
BioAtla
BCAB
$26.7M
| $49.4M | 4.94% | 2,515,424 | – | – |
|
4
United Therapeutics
UTHR
$13.8B
| $35.5M | 3.55% | 164,300 +62,500 | +61% | +$13.5M |
|
5
AstraZeneca
AZN
$248B
| $27.9M | 2.79% | 478,596 +159,200 | +50% | +$9.27M |
|
6
Surmodics
SRDX
$487M
| $25.7M | 2.57% | 532,757 +151,235 | +40% | +$7.28M |
|
7
Enanta Pharmaceuticals
ENTA
$180M
| $23.8M | 2.38% | 318,275 +135,875 | +74% | +$10.2M |
|
|
THER
8
DELISTED
THERATECHNOLOGIES INC COM
THER
| $23.3M | 2.33% | 7,692,082 +79,699 | +1% | +$241K |
|
9
Neuropace
NPCE
$303M
| $23.3M | 2.33% | 2,309,003 +638,867 | +38% | +$6.44M |
|
|
10
FibroGen
FGEN
$47.8M
| $21.9M | 2.19% | +1,550,497 | New | +$21.9M |
|
11
Nurix Therapeutics
NRIX
$714M
| $21.5M | 2.15% | 743,238 +479,338 | +182% | +$13.9M |
|
12
Natera
NTRA
$23.1B
| $21.3M | 2.13% | 227,599 +88,610 | +64% | +$8.28M |
|
13
iRadimed
IRMD
$921M
| $20.8M | 2.08% | 450,030 -649 | -0.1% | -$30K |
|
|
14
Smith & Nephew
SNN
$16.3B
| $20.5M | 2.06% | +593,200 | New | +$20.5M |
|
|
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $20.5M | 2.05% | 810,940 -68,963 | -8% | -$1.75M |
|
|
APEN
16
DELISTED
Apollo Endosurgery, Inc.
APEN
| $19.3M | 1.94% | +2,295,100 | New | +$19.3M |
|
|
EDAP
17
EDAP TMS
EDAP
$84.5M
| $18.9M | 1.89% | 3,148,609 +192,242 | +7% | +$1.15M |
|
18
Organogenesis Holdings
ORGO
$653M
| $18.5M | 1.85% | 1,999,087 +1,359,200 | +212% | +$12.6M |
|
|
19
C4 Therapeutics
CCCC
$185M
| $18.1M | 1.81% | 561,122 -189,511 | -25% | -$6.1M |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.9M | 1.79% | 1,068,376 -24,644 | -2% | -$412K |
|
21
Krystal Biotech
KRYS
$4.27B
| $16M | 1.6% | 228,437 +102,908 | +82% | +$7.2M |
|
|
22
CVS Health
CVS
$92.8B
| $14.2M | 1.43% | +138,000 | New | +$14.2M |
|
23
AngioDynamics
ANGO
$417M
| $14.2M | 1.42% | 515,450 +272,925 | +113% | +$7.53M |
|
24
Steris
STE
$24.1B
| $12.7M | 1.27% | +52,100 | New | +$12.7M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $11.8M | 1.19% | 378,997 +163,300 | +76% | +$5.1M |
|